Your browser doesn't support javascript.
loading
Genetic mechanisms underlying arrhythmogenic mitral valve prolapse: Current and future perspectives.
Levy, Sydney; Sharaf Dabbagh, Ghaith; Giudicessi, John R; Haqqani, Haris; Khanji, Mohammed Y; Obeng-Gyimah, Edmond; Betts, Megan N; Ricci, Fabrizio; Asatryan, Babken; Bouatia-Naji, Nabila; Nazarian, Saman; Chahal, C Anwar A.
Afiliação
  • Levy S; Byram Hills High School, Armonk, New York.
  • Sharaf Dabbagh G; Harvard College, Cambridge, Massachusetts.
  • Giudicessi JR; Center for Inherited Cardiovascular Diseases, WellSpan Health, Lancaster, Pennsylvania.
  • Haqqani H; Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan.
  • Khanji MY; Divisions of Heart Rhythm Services and Circulatory Failure, Departments of Cardiovascular Medicine, Molecular Pharmacology, and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota.
  • Obeng-Gyimah E; The Prince Charles Hospital, Queensland, Australia.
  • Betts MN; Byram Hills High School, Armonk, New York.
  • Ricci F; NIHR Barts Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
  • Asatryan B; Newham University Hospital, Barts Health NHS Trust, London, United Kingdom.
  • Bouatia-Naji N; Clinical Cardiac Electrophysiology, VT and Complex Ablation Program, WellSpan Health, York, Pennsylvania.
  • Nazarian S; Center for Inherited Cardiovascular Diseases, WellSpan Health, Lancaster, Pennsylvania.
  • Chahal CAA; Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.
Heart Rhythm O2 ; 4(9): 581-591, 2023 Sep.
Article em En | MEDLINE | ID: mdl-37744942
ABSTRACT
Mitral valve prolapse (MVP) is a heart valve disease that is often familial, affecting 2%-3% of the general population. MVP with or without mitral regurgitation can be associated with an increased risk of ventricular arrhythmias and sudden cardiac death (SCD). Research on familial MVP has specifically focused on genetic factors, which may explain the heritable component of the disease estimated to be present in 20%-35%. Furthermore, the structural and electrophysiological substrates underlying SCD/ventricular arrhythmia risk in MVP have been studied postmortem and in the electrophysiology laboratory, respectively. Understanding how familial MVP and rhythm disorders are related may help patients with MVP by individualizing risk and working to develop effective management strategies. This contemporary, state-of-the-art, expert review focuses on genetic factors and familial components that underlie MVP and arrhythmia and encapsulates clinical, genetic, and electrophysiological issues that should be the objectives of future research.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article